Tag Archives | Prostate Cancer Marketing Strategy

2011 ESMO ESTRO ECCO Cancer Congress Prostate Cancer News

It’s exciting to see new products that make a difference to patients come to market. Multiple treatments improve overall survival (OS) in prostate cancer patients: docetaxel, cabazitaxel, sipuleucel-T, abiraterone acetate and now, radium-223 choloride. The phase 3 trial results for radium 223 chloride were presented at the 2011 European Multidisciplinary Cancer Congress (ESMO, ECCO, ESTRO) […]

Continue Reading

Prostate Cancer Market Research

Do you have a need to understand the fast moving prostate cancer market and its competitive dynamics? If so, please contact us as we offer a number of services in support of prostate cancer marketing and new products.  The team at Icarus Consultants has in-depth knowledge of this therapeutic area. Last week, Pieter Droppert wrote […]

Continue Reading

AUA 2011 Treatment of prostate cancer bone metastases

Men in the United States have a 1 in 6 chance of developing prostate cancer in their lifetime. It is, therefore, likely that we all know somebody who has been touched by the disease.  To put this data in perspective, approximately 1 in 8 women in the United States will develop breast cancer. Bone metastases […]

Continue Reading

Zytiga (abiraterone acetate) price will impact the Prostate Cancer market following FDA approval

Sally Church on Pharma Strategy Blog has written about the FDA approval yesterday of Ortho Biotech’s ($JNJ) abiraterone acetate, brand name Zytiga for the treatment of castration resistant prostate cancer in patients who have received prior chemotherapy with docetaxel. The final data showed a 4.6 month increase in overall survival (OS) in these very sick […]

Continue Reading

New drugs will change the Prostate Cancer market

As marketing strategy consultants, it’s fascinating to watch the dynamics of a pharmaceutical market in rapid evolution. With three new therapies for prostate cancer approved last year (cabazitaxel, denosumab, sipuleucel-T) and the approval of abiraterone acetate expected this month, the prostate cancer market is a fast changing one. This is really good news for patients, […]

Continue Reading

error: Content is protected !!